Cargando…
Psychedelic therapy in the treatment of addiction: the past, present and future
Psychedelic therapy has witnessed a resurgence in interest in the last decade from the scientific and medical communities with evidence now building for its safety and efficacy in treating a range of psychiatric disorders including addiction. In this review we will chart the research investigating t...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10291338/ https://www.ncbi.nlm.nih.gov/pubmed/37377473 http://dx.doi.org/10.3389/fpsyt.2023.1183740 |
_version_ | 1785062673751212032 |
---|---|
author | Zafar, Rayyan Siegel, Maxim Harding, Rebecca Barba, Tommaso Agnorelli, Claudio Suseelan, Shayam Roseman, Leor Wall, Matthew Nutt, David John Erritzoe, David |
author_facet | Zafar, Rayyan Siegel, Maxim Harding, Rebecca Barba, Tommaso Agnorelli, Claudio Suseelan, Shayam Roseman, Leor Wall, Matthew Nutt, David John Erritzoe, David |
author_sort | Zafar, Rayyan |
collection | PubMed |
description | Psychedelic therapy has witnessed a resurgence in interest in the last decade from the scientific and medical communities with evidence now building for its safety and efficacy in treating a range of psychiatric disorders including addiction. In this review we will chart the research investigating the role of these interventions in individuals with addiction beginning with an overview of the current socioeconomic impact of addiction, treatment options, and outcomes. We will start by examining historical studies from the first psychedelic research era of the mid-late 1900s, followed by an overview of the available real-world evidence gathered from naturalistic, observational, and survey-based studies. We will then cover modern-day clinical trials of psychedelic therapies in addiction from first-in-human to phase II clinical trials. Finally, we will provide an overview of the different translational human neuropsychopharmacology techniques, including functional magnetic resonance imaging (fMRI) and positron emission tomography (PET), that can be applied to foster a mechanistic understanding of therapeutic mechanisms. A more granular understanding of the treatment effects of psychedelics will facilitate the optimisation of the psychedelic therapy drug development landscape, and ultimately improve patient outcomes. |
format | Online Article Text |
id | pubmed-10291338 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-102913382023-06-27 Psychedelic therapy in the treatment of addiction: the past, present and future Zafar, Rayyan Siegel, Maxim Harding, Rebecca Barba, Tommaso Agnorelli, Claudio Suseelan, Shayam Roseman, Leor Wall, Matthew Nutt, David John Erritzoe, David Front Psychiatry Psychiatry Psychedelic therapy has witnessed a resurgence in interest in the last decade from the scientific and medical communities with evidence now building for its safety and efficacy in treating a range of psychiatric disorders including addiction. In this review we will chart the research investigating the role of these interventions in individuals with addiction beginning with an overview of the current socioeconomic impact of addiction, treatment options, and outcomes. We will start by examining historical studies from the first psychedelic research era of the mid-late 1900s, followed by an overview of the available real-world evidence gathered from naturalistic, observational, and survey-based studies. We will then cover modern-day clinical trials of psychedelic therapies in addiction from first-in-human to phase II clinical trials. Finally, we will provide an overview of the different translational human neuropsychopharmacology techniques, including functional magnetic resonance imaging (fMRI) and positron emission tomography (PET), that can be applied to foster a mechanistic understanding of therapeutic mechanisms. A more granular understanding of the treatment effects of psychedelics will facilitate the optimisation of the psychedelic therapy drug development landscape, and ultimately improve patient outcomes. Frontiers Media S.A. 2023-06-12 /pmc/articles/PMC10291338/ /pubmed/37377473 http://dx.doi.org/10.3389/fpsyt.2023.1183740 Text en Copyright © 2023 Zafar, Siegel, Harding, Barba, Agnorelli, Suseelan, Roseman, Wall, Nutt and Erritzoe. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Psychiatry Zafar, Rayyan Siegel, Maxim Harding, Rebecca Barba, Tommaso Agnorelli, Claudio Suseelan, Shayam Roseman, Leor Wall, Matthew Nutt, David John Erritzoe, David Psychedelic therapy in the treatment of addiction: the past, present and future |
title | Psychedelic therapy in the treatment of addiction: the past, present and future |
title_full | Psychedelic therapy in the treatment of addiction: the past, present and future |
title_fullStr | Psychedelic therapy in the treatment of addiction: the past, present and future |
title_full_unstemmed | Psychedelic therapy in the treatment of addiction: the past, present and future |
title_short | Psychedelic therapy in the treatment of addiction: the past, present and future |
title_sort | psychedelic therapy in the treatment of addiction: the past, present and future |
topic | Psychiatry |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10291338/ https://www.ncbi.nlm.nih.gov/pubmed/37377473 http://dx.doi.org/10.3389/fpsyt.2023.1183740 |
work_keys_str_mv | AT zafarrayyan psychedelictherapyinthetreatmentofaddictionthepastpresentandfuture AT siegelmaxim psychedelictherapyinthetreatmentofaddictionthepastpresentandfuture AT hardingrebecca psychedelictherapyinthetreatmentofaddictionthepastpresentandfuture AT barbatommaso psychedelictherapyinthetreatmentofaddictionthepastpresentandfuture AT agnorelliclaudio psychedelictherapyinthetreatmentofaddictionthepastpresentandfuture AT suseelanshayam psychedelictherapyinthetreatmentofaddictionthepastpresentandfuture AT rosemanleor psychedelictherapyinthetreatmentofaddictionthepastpresentandfuture AT wallmatthew psychedelictherapyinthetreatmentofaddictionthepastpresentandfuture AT nuttdavidjohn psychedelictherapyinthetreatmentofaddictionthepastpresentandfuture AT erritzoedavid psychedelictherapyinthetreatmentofaddictionthepastpresentandfuture |